Acinetobacter baumannii: Epidemiology, Antimicrobial Resistance, and Treatment Options

ANTIMICROBIAL RESISTANCE George M. Eliopoulos, Section Editor INVITED ARTICLE Acinetobacter baumannii: Epidemiology, Antimicrobial Resistance, and Treatment Options Lisa L. Maragakis 1,2 and Trish M. Perl 1,2 1 Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, and 2 Department of Hospital Epidemiology and Infection Control, Johns Hopkins Medical Institutions, Baltimore, Maryland Multidrug-resistant Acinetobacter baumannii is recognized to be among the most difficult antimicrobial-resistant gramnegative bacilli to control and treat. Increasing antimicrobial resistance among Acinetobacter isolates has been documented, although definitions of multidrug resistance vary in the literature. A. baumannii survives for prolonged periods under a wide range of environmental conditions. The organism causes outbreaks of infection and health care associated infections, including bacteremia, pneumonia, meningitis, urinary tract infection, and wound infection. Antimicrobial resistance greatly limits the therapeutic options for patients who are infected with this organism, especially if isolates are resistant to the carbapenem class of antimicrobial agents. Because therapeutic options are limited for multidrug-resistant Acinetobacter infection, the development or discovery of new therapies, well-controlled clinical trials of existing antimicrobial regimens and combinations, and greater emphasis on the prevention of health care associated transmission of multidrug-resistant Acinetobacter infection are essential. Multidrug-resistant Acinetobacter baumannii is a rapidly emerging pathogen in the health care setting, where it causes infections that include bacteremia, pneumonia, meningitis, urinary tract infection, and wound infection. The organism s ability to survive under a wide range of environmental conditions and to persist for extended periods of time on surfaces make it a frequent cause of outbreaks of infection and an endemic, health care associated pathogen [1, 2]. EPIDEMIOLOGY Risk factors for colonization or infection with multidrug-resistant Acinetobacter species include prolonged length of hospital stay, exposure to an intensive care unit (ICU), receipt of mechanical ventilation, colonization pressure, exposure to antimicrobial agents, recent surgery, invasive procedures, and underlying severity of illness [1, 3]. Widespread environmental contamination is often demonstrated, and outbreaks of infec- Received 10 September 2007; accepted 8 December 2007; electronically published 13 March 2008. Reprints or correspondence: Dr. Lisa L. Maragakis, Dept. of Hospital Epidemiology and Infection Control, Johns Hopkins Hospital, 600 N. Wolfe St., Osler 425, Baltimore, MD 21287 (lmaraga1@jhmi.edu). Clinical Infectious Diseases 2008; 46:1254 63 2008 by the Infectious Diseases Society of America. All rights reserved. 1058-4838/2008/4608-0020$15.00 DOI: 10.1086/529198 tion have been traced to respiratory care equipment, wound care procedures, humidifiers, and patient care items [4 13]. Wilks et al. [8] reported a recent outbreak of multidrug-resistant Acinetobacter infection, with environmental contamination found on curtains, laryngoscope blades, patient lifting equipment, door handles, mops, and keyboards. Medical equipment has been implicated, emphasizing the need for special attention to disinfection of shared items and extra caution with respiratory care and wound care procedures [4, 5, 7]. One or more epidemic Acinetobacter clones often coexist with endemic strains, making it difficult to detect and control transmission [14, 15]. Table 1 outlines various infection control and prevention methods for multidrug-resistant Acinetobacter infection. Investigators often report interruption of transmission after reinforcement of existing infection control and prevention standards, such as hand hygiene, standard precautions, barrier precautions, and thorough environmental cleaning and disinfection [8, 16, 17]. Other transmission is more difficult to halt, requiring cohorting of patients, dedicated staff assignments, active surveillance cultures, and closure of entire ICUs [11 13, 18 23]. Most reports of successful control involve multiple interventions, making it difficult to evaluate the efficacy of each intervention individually [24]. Further investigation of the efficacy and cost-effectiveness of various infection control strat- 1254 CID 2008:46 (15 April) ANTIMICROBIAL RESISTANCE

Table 1. Method Methods for control and prevention of multidrug-resistant Acinetobacter infection. Comments Point source control Standard precautions Contact barrier precautions Environmental cleaning and disinfection Cohorting of patients Cohorting of health care personnel Clinical unit closure Antimicrobial stewardship Surveillance Effective in the outbreak setting when a point source is identified Includes hand hygiene, correct and consistent glove use, and appropriate use of gowns and eye protection; reported compliance among healthcare personnel is often poor Includes dedicated patient care equipment and gowns and gloves for health care personnel on entry to an isolation room Widespread environmental contamination is often reported in the epidemic setting, and environmental reservoirs likely play a role in the endemic setting as well Grouping colonized and infected patients into a designated unit or part of a unit Designating staff to care for only patients colonized or infected with the organism Required in some outbreak settings to interrupt transmission and allow for thorough environmental disinfection Programs to promote judicious antimicrobial use and prevent emergence of resistance Passive or active surveillance can identify infected or colonized patients so that interventions can be implemented egies to prevent transmission of multidrug-resistant Acinetobacter infection are needed. In addition to transmission, emergence of resistance occurs in the context of selective pressure from broad-spectrum antimicrobial therapy, such as therapy involving carbapenems or third-generation cephalosporins [25, 26]. The relative contributions of antimicrobial selective pressure and transmission between patients on the emergence of multidrug-resistant Acinetobacter species are not known. In many health care institutions, endemic, multidrug-resistant Acinetobacter infection demonstrates complex epidemiologic profiles and coexistence of multiple strain types. Abbo et al. [27] studied 118 patients with multidrug-resistant Acinetobacter infection in Israel and found 10 different PFGE-typed clones, as well as many small clusters of patients with no common source identified, despite molecular testing and extensive investigation. Multidrug-resistant Acinetobacter infection has been reported among patients residing in rehabilitation and long term care facilities, as well as in acute care hospitals [28, 29]. Several factors work together to maintain the presence of multidrug-resistant Acinetobacter species in the health care setting, including the presence of susceptible patients, the presence of patients already colonized or infected with the organism, selective pressure from antimicrobial use, and incomplete compliance with infection control procedures [24] (figure 1). Molecular-based strain typing by PFGE or other methods can be used to identify outbreaks of infection and to monitor interinstitutional, regional, and international transmission of multidrug-resistant Acinetobacter species [30, 31]. Nemec et al. [31] used ribotyping and amplified fragment length polymorphisms to demonstrate the genetic relatedness of Acinetobacter isolates in western Europe. Investigators used PFGE to demonstrate interinstitutional spread of carbapenem-resistant Acinetobacter infection among acute care hospitals in locales including New York, Argentina, the United Kingdom, and the Iberian Peninsula [32 35]. Gales et al. [36] used PFGE to demonstrate the spread of epidemic Acinetobacter clones between Brazil and Argentina. Multidrug-resistant Acinetobacter deep wound infections, osteomyelitis, respiratory infections, and bacteremia have been reported among military personnel with traumatic injuries during the conflicts in Iraq and Afghanistan [37 40]. Theories that previously colonized soldiers are autoinoculated or that Acinetobacter species from local soil or water are introduced during traumatic injury have not been supported by cultures of specimens obtained from healthy soldiers, soil samples, water samples, or samples from fresh wounds [41 44]. Current literature suggests that these infections are associated with health care and are acquired by soldiers in medical facilities during the processes of stabilization, emergency treatment, and evacuation through the military medical system [37, 39, 42, 43, 45, 46]. The potential for introduction of new, virulent, multidrugresistant Acinetobacter strains into hospitals by returning soldiers is a concern that warrants ongoing surveillance and careful attention to infection control measures [39, 47, 48]. IMPACT ON PATIENT OUTCOMES Because multidrug-resistant Acinetobacter infection usually occurs in severely ill patients in the ICU, the associated crude mortality rate is high, ranging from 26% to 68% [49 51]. It has proven to be difficult, however, to determine the attributable mortality of these infections independent of patients severe underlying illnesses. Recent studies and a systematic review concluded that Acinetobacter infection or colonization is associated with increased mortality [52 54]. Many of these ANTIMICROBIAL RESISTANCE CID 2008:46 (15 April) 1255

Figure 1. Factors leading to the emergence and transmission of multidrug-resistant (MDR) Acinetobacter species. ICU, intensive care unit. studies were limited by small sample sizes, methodological differences, and failure to adequately control for patients severity of illness. Other studies that rigorously controlled for severity of illness did not find Acinetobacter infection to be independently associated with increased mortality [1, 49, 55, 56]. An alternative explanation is that Acinetobacter infection is a marker of increased mortality in patients with severe underlying illness but not an independent predictor of mortality [55]. Mortality may be related to the extent of antimicrobial resistance, the effectiveness of empirical therapy, and the availability of definitive therapeutic options. A recent matched cohort study from Korea found that administration of ineffective empirical antimicrobial therapy for Acinetobacter bacteremia was an independent predictor of 30-day mortality [51]. However, other studies have found poor correlation between patient mortality and the empirical choice of antimicrobial agents to which Acinetobacter infection was resistant [49, 55, 57 59]. Acinetobacter infection is associated with increased morbidity and a prolonged length of hospital stay. A retrospective, matched cohort study found that patients with Acinetobacter bacteremia had a 5-day excess length of mechanical ventilator dependence and ICU stay, compared with critically ill patients without Acinetobacter infection [56]. Multidrug-resistant Acinetobacter infection was found to significantly prolong the duration of ICU stay (by 6 days) and the median duration of hospitalization (by 18 days) [49, 60]. One study found no evidence of a prolonged length of ICU stay for patients with Acinetobacter ventilator-associated pneumonia [61]. The impact on length of stay may depend on the type of infection and the extent of antimicrobial resistance. ANTIMICROBIAL RESISTANCE Antimicrobial resistance among Acinetobacter species has increased substantially in the past decade [62]. The capacity of Acinetobacter species for extensive antimicrobial resistance may be due in part to the organism s relatively impermeable outer membrane and its environmental exposure to a large reservoir of resistance genes [63]. Definitions of multidrug-resistant Acinetobacter species vary, referring to a wide array of genotypes and phenotypes [64]. Two of the most common definitions of multidrug resistance are carbapenem resistance or resistance to 3 classes of antimicrobials [64]. Some strains are susceptible only to polymyxins peptide antibiotics that are not routinely used because of earlier reports about toxicities. Strains that demonstrate resistance to all antimicrobial agents, including polymyxins, have also been reported in the literature, making treatment of these infections extremely difficult and in some cases impossible [65, 66]. Mechanisms of resistance. Resistance mechanisms for Acinetobacter species are similar to those for Pseudomonas species, although Acinetobacter species have not been studied as extensively [67, 68]. The mechanisms of resistance generally fall into 3 categories: (1) antimicrobial-inactivating enzymes, (2) reduced access to bacterial targets, or (3) mutations that change targets or cellular functions [68]. For the first category, Acinetobacter species possess a wide array of b-lactamases that hydrolyze and confer resistance to penicillins, cephalosporins, and carbapenems. AmpC cephalosporinases are chromosomally encoded and confer resistance to broad-spectrum cephalosporins [63, 67]. Recently, a large number of class D OXA-type 1256 CID 2008:46 (15 April) ANTIMICROBIAL RESISTANCE

enzymes with activity against carbapenems were characterized in locations that include Scotland, Spain, France, Japan, Singapore, China, Brazil, Cuba, and Kuwait [69, 70]. Some Acinetobacter strains express class B metallo b-lactamases (MBLs), such as VIM and IMP, which hydrolyze a broad array of antimicrobial agents, including carbapenems [67]. MBLs pose a significant threat because they are often located on mobile genetic elements easily transferred among bacteria [63, 67]. Many variants exist, and both IMP and VIM have been found worldwide in a wide array of bacterial species, including Acinetobacter species [67, 71, 72]. Porin channels and other outer membrane proteins are important for transport of antimicrobial agents into the cell to gain access to bacterial targets. Carbapenem resistance in Acinetobacter species has been linked to the loss of proteins thought to be porin channels from the outer membrane [67, 73, 74]. It is likely that b-lactamases and outer-membrane alterations work together to confer resistance to b-lactam agents [63]. Acinetobacter species possess efflux pumps that are capable of actively removing a broad range of antimicrobial agents from the bacterial cell [63]. The third category of resistance mechanisms involves point mutations that alter bacterial targets or functions, decreasing the affinity for antimicrobial agents or up-regulating cellular functions, such as the production of efflux pumps or other proteins. Resistance to colistin is thought to be mediated by changes in the bacterial cell membrane that interfere with the agent s ability to bind bacterial targets [75]. This type of mechanism is also seen in Acinetobacter resistance to quinolone agents from mutations in the bacterial targets gyra and parc topoisomerase enzymes [63]. Acinetobacter species can acquire resistance genes from other organisms; mutations leading to resistance can develop over time in Acinetobacter strains; or subpopulations with preexisting resistance may emerge and become dominant under antimicrobial selective pressure [69]. These 3 processes are not mutually exclusive and likely function together to explain emerging resistance among Acinetobacter species. A recent comparative genomic study of an epidemic, multidrug-resistant Acinetobacter strain in France found a large genomic resistance island containing 45 resistance genes that appeared to have been acquired from Pseudomonas, Salmonella, or Escherichia genera [76]. The emergence of antimicrobial-resistant Acinetobacter species is due to both selective pressure exerted by the use of broad-spectrum antimicrobials and transmission of strains among patients, although the relative contributions of these mechanisms are not yet known [14, 77]. TREATMENT Carbapenems. Increasing antimicrobial resistance leaves few therapeutic options, and there are no well-designed clinical trials to compare treatment regimens for multidrug-resistant Acinetobacter infection. Available data are from in vitro, animal, and observational studies. Carbapenems remain the treatment of choice if isolates retain susceptibility to this antimicrobial class. The Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) surveillance program has documented discordance that favors imipenem as the more potent agent, compared with meropenem, for treatment of multidrug-resistant Acinetobacter infection [78, 79]. The converse result was reported in Greece [80]. Efflux pumps may affect meropenem to a greater degree, whereas specific b-lactamases hydrolyze imipenem more efficiently [80]. Susceptibility testing of imipenem does not predict susceptibility to meropenem or vice versa [78]. Unfortunately, carbapenem-resistant Acinetobacter isolates are increasingly reported worldwide. b-lactamase inhibitors. b-lactamase inhibitors, particularly sulbactam, have intrinsic activity against many Acinetobacter strains. The presence of a b-lactam agent (e.g., ampicillin) in combination with the b-lactamase inhibitor does not appear to contribute activity or synergy [81, 82]. Monotherapy with sulbactam is not recommended for severe Acinetobacter infection. However, Wood et al. [83] reported successful use of sulbactam to treat 14 patients with multidrug-resistant Acinetobacter ventilator-associated pneumonia, finding no difference in clinical outcomes between sulbactam-treated patients and 63 patients who received imipenem. Levin et al. [84] reported a cure rate of 67% using ampicillin-sulbactam to treat carbapenem-resistant Acinetobacter infection, but good patient outcomes were associated with lower severity of illness. The results of antimicrobial susceptibility tests (e.g., with agar dilution or the Etest) of b lactam/b-lactamase combinations at fixed concentrations must be interpreted with caution, because they may indicate susceptibility when an isolate is actually resistant [82]. Tigecycline. Tigecycline, a relatively new glycylcycline agent, has bacteriostatic activity against multidrug-resistant Acinetobacter species [85, 86]. High-level resistance to tigecycline has been detected among some multidrug-resistant Acinetobacter isolates, and there is concern that the organism can rapidly evade this antimicrobial agent by upregulating chromosomally mediated efflux pumps [68, 87 91]. Peleg et al. [89] reported 2 cases of multidrug-resistant Acinetobacter bacteremia that occurred while patients were receiving tigecycline for another indication. Two recent studies documented overexpression of a multidrug efflux pump in Acinetobacter isolates with decreased susceptibility to tigecycline [92, 93]. Given these findings and concern about whether adequate peak serum concentrations can be achieved, tigecycline is best reserved for salvage therapy, with administration determined in consultation with an infectious diseases specialist [89]. Aminoglycosides. Aminoglycoside agents, such as tobramycin and amikacin, are therapeutic options for infection with ANTIMICROBIAL RESISTANCE CID 2008:46 (15 April) 1257

Table 2. Studies of antimicrobial combinations against multidrug-resistant Acinetobacter infection. Study Year Study method Combination Results/comments Giamarellos-Bourboulis et al. [110] 2001 In vitro Colistin and rifampin In vitro synergy Petrosillo et al. [111] 2005 Case series Colistin and rifampin Microbiologic cure in 64% of 14 patients with VAP Pantopoulou et al. [112] 2007 Animal study Colistin and rifampin Enhanced activity against experimental thigh infection in neutropenic rats Gleeson et al. [123] 2005 Case report Meropenem and rifampin Successful treatment of meningitis after meropenem monotherapy failed Montero et al. [113] 2004 Animal study Colistin and rifampin, imipenem and rifampin, tobramycin and rifampin, imipenem and tobramycin The best regimens in a mouse pneumonia model Saballs et al. [114] 2006 Clinical pilot study Imipenem and rifampin Cautions against use of this regimen due to high failure rate and emergence of rifampin resistance in 70% of patients Rodriguez-Hernandez et al. [115] 2000 Animal study Imipenem and amikacin Combination offered no advantage over imipenem monotherapy in a mouse pneumonia model Bernabeu-Wittel et al. [116] 2005 Animal study Imipenem and amikacin Combination was worse than imipenem alone in a guinea pig pneumonia model, despite evidence of in vitro synergy Haddad et al. [117] 2005 In vitro Imipenem and amikacin; imipenem and In vitro synergy colistin Ko et al. [118] 2004 Animal study Meropenem and sulbactam In vitro synergy and increased survival in a mouse infection model Kiffer et al. [119] 2005 In vitro Meropenem and sulbactam In vitro synergy Sader et al. [122] 2005 In vitro Cefipime and sulbactam In vitro synergy Kasiakou et al. [102] 2005 Case series Colistin and another agent a 67% of 50 patients with severe Acinetobacter or Pseudomonas infection were cured or improved Sobieszczyk et al. [121] 2004 Case series Colistin and another agent a 79% of 25 patients with Acinetobacter or Pseudomonas pneumonia survived until the end of therapy NOTE. ICU, intensive care unit; VAP, ventilator-associated pneumonia. a Other agents included meropenem, imipenem, aminoglycosides, ampicillin-sulbactam, piperacillin-clavulanate, and ciprofloxacin. multidrug-resistant Acinetobacter isolates that retain susceptibility. These agents are usually used in conjunction with another active antimicrobial agent. Many multidrug-resistant Acinetobacter isolates retain intermediate susceptibility to amikacin or tobramycin; resistance to this class of agents is increasingly associated with aminoglycoside-modifying enzymes or efflux pump mechanisms. Polymyxin therapy. Given limited therapeutic options, clinicians have returned to the use of polymyxin B or polymyxin E (colistin) for the most drug-resistant Acinetobacter infections [94, 95]. Colistin acts by disturbing the bacterial cell membrane, thus increasing permeability, leading to cell death [94]. Colistin is bactericidal against Acinetobacter species, and its effect is concentration dependent [95]. Resistance to polymyxins has been reported, possibly as a result of outer cell membrane alterations or an efflux pump mechanism [65, 66, 94, 95]. Observational studies have reported rates of cure or improvement for colistin of 57% 77% among severely ill patients with multidrug-resistant Acinetobacter infections, including pneumonia, bacteremia, sepsis, intra-abdominal infection, and CNS infection [96 99]. Although high-quality pharmacokinetic data are lacking, colistin is reported to have relatively poor lung and CSF distribution, and clinical outcomes vary for different types of infections [96]. Despite an overall good outcome rate of 67%, Levin et al. [96] found a lower response rate of 25% for patients with pneumonia due to multidrug-resistant, gram-negative bacilli who were treated with parenteral colistin. Other studies have reported more favorable clinical response rates (56% 61%) for parenteral colistin treatment of multidrug-resistant Acinetobacter ventilator-associated pneumonia [100 103]. There are case reports of successful treatment of multidrugresistant Acinetobacter meningitis with parenteral colistin, but its efficacy for this condition remains unclear [104, 105]. Several case reports and case series report the use of intraventricular or intrathecal polymyxin therapy, with or without parenteral therapy, for the treatment of gram-negative bacterial meningitis [104, 106 108]. A recent review of 31 reports involving 64 episodes of gram-negative bacterial meningitis found a cure rate of 80%, including cure for 10 (91%) of 11 patients with Acinetobacter meningitis [109]. The majority of patients received systemic antimicrobial therapy in addition to local administration of polymyxin. Neurologic toxicity occurred primarily in reports published before 1970, and the most common 1258 CID 2008:46 (15 April) ANTIMICROBIAL RESISTANCE

manifestation was meningeal irritation, which was apparently dose-dependent and reversible [109]. Overall, there is insufficient evidence to draw conclusions regarding the efficacy, safety, or pharmacokinetic properties of colistin for treatment of CNS infection, although it remains an important option for salvage therapy [104]. Data are lacking on the pharmacokinetics, pharmacodynamics, and toxicodynamics of colistin. Earlier methods of measuring serum concentrations of the drug were unable to adequately distinguish concentrations of colistimethate, the nonactive prodrug, from concentrations of colistin [95]. There are inconsistencies among manufacturers regarding the recommended dosing of colistin and the units of measurement employed [95]. Data suggest that current recommended dosing regimens may lead to serum levels of colistin that are less than the MIC for Acinetobacter infection [95]. These problems highlight the need for careful pharmacologic studies and the importance of attention to formulation and dosing in clinical care and research studies. Synergy and combination therapy. A lack of controlled clinical trials makes it difficult to evaluate the role of synergy or combination therapy for multidrug-resistant Acinetobacter infection. Most available data are from uncontrolled case series, animal models, or in vitro studies. The studies summarized in table 2 investigated various combinations of rifampin, sulbactam, aminoglycoside agents, colistin, carbapenems, and other agents against multidrug-resistant Acinetobacter infection [102, 110 123]. Studies have found conflicting results for the same antimicrobial combinations. Montero et al. [113] studied a mouse model of multidrug-resistant Acinetobacter pneumonia and found that the combinations of rifampin with imipenem, tobramycin, or colistin were the most effective regimens. A follow-up clinical pilot study, however, cautioned against the use of rifampin plus imipenem for treatment of carbapenem-resistant Acinetobacter infection, because investigators observed a high failure rate and documented the emergence of rifampin resistance in 70% of the patients who were treated with this regimen [114]. In a guinea pig model, the combination of imipenem and amikacin was found to be worse than imipenem alone for treatment of imipenem-resistant pneumonia, despite the demonstration of in vitro synergy between the agents [116]. The clinical utility of in vitro synergy remains unclear. Most results for combination therapy are comparable to cure rates reported for parenteral colistin alone, and the wide variety of other agents used limits the ability to draw conclusions regarding combination therapy. Controlled clinical studies are needed to determine whether any antimicrobial combinations translate into useful therapeutic strategies. Li et al. [124] found heteroresistance (i.e., subpopulations with varying levels of resistance to colistin) in 15 of 16 colistinsusceptible Acinetobacter isolates studied in vitro. Serial passage of the isolates in the presence of colistin increased the proportion of colistin-resistant subpopulations. Owen et al. [125] also found in vitro evidence of heteroresistance, suggesting that combination therapy may be advisable to prevent the emergence of colistin resistance during monotherapy. CONCLUSIONS Despite a reputation for relatively low virulence, multidrugresistant Acinetobacter infection poses a formidable threat to patients. The cause of many outbreaks, this organism is increasingly endemic in the health care setting. Antimicrobial resistance is increasing, likely as a result both of the emergence of resistance in the context of antimicrobial pressure and of health care associated transmission of drug-resistant strains. Multidrug-resistant Acinetobacter infections have an extremely high crude mortality rate and occur most frequently in severely ill patients. Although the attributable mortality of multidrugresistant Acinetobacter infections is debatable, these infections are clearly associated with increased time on mechanical ventilation, in the ICU, and in the hospital. Treatment options are severely limited, and there have been, to our knowledge, no controlled trials to guide therapeutic choices. Carbapenems and colistin are the agents of choice for the most drug-resistant infections. The role of other agents and combination therapy remains unclear. More data are needed on the pharmacokinetics, pharmacodynamics, and appropriate dosing of colistin, especially in light of the discovery of heteroresistance. Given the lack of good therapeutic options, the development of new therapies, well-controlled clinical trials of existing regimens and antimicrobial combinations, more research, and greater emphasis on the prevention of health care-associated transmission of multidrug-resistant Acinetobacter infection are essential. Acknowledgments We thank Benedict John Frederick for his assistance developing figure 1. Financial support. Centers for Disease Control and Prevention (1 K01 CI000300 and 1 R01 CI000530). Potential conflicts of interest. T.M.P. has been on advisory boards for Pfizer, Replidyne, and 3M; has received recent research funding from 3M and Sage; and has received a speaker honorarium from Ortho McNeil. L.L.M.: no conflicts. References 1. Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006; 42:692 9. 2. Jawad A, Heritage J, Snelling AM, Gascoyne-Binzi DM, Hawkey PM. Influence of relative humidity and suspending menstrua on survival of Acinetobacter spp. on dry surfaces. J Clin Microbiol 1996; 34: 2881 7. 3. Playford EG, Craig JC, Iredell JR. Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: risk factors for acquisition, infection and their consequences. J Hosp Infect 2007; 65:204 11. ANTIMICROBIAL RESISTANCE CID 2008:46 (15 April) 1259

4. Bernards AT, Harinck HI, Dijkshoorn L, van der Reijden TJ, van den Broek PJ. Persistent Acinetobacter baumannii? Look inside your medical equipment. Infect Control Hosp Epidemiol 2004; 25:1002 4. 5. Maragakis LL, Cosgrove SE, Song X, et al. An outbreak of multidrugresistant Acinetobacter baumannii associated with pulsatile lavage wound treatment. JAMA 2004; 292:3006 11. 6. Das I, Lambert P, Hill D, Noy M, Bion J, Elliott T. Carbapenemresistant Acinetobacter and role of curtains in an outbreak in intensive care units. J Hosp Infect 2002; 50:110 4. 7. Villegas MV, Hartstein AI. Acinetobacter outbreaks, 1977 2000. Infect Control Hosp Epidemiol 2003; 24:284 95. 8. Wilks M, Wilson A, Warwick S, et al. Control of an outbreak of multidrug-resistant Acinetobacter baumannii calcoaceticus colonization and infection in an intensive care unit (ICU) without closing the ICU or placing patients in isolation. Infect Control Hosp Epidemiol 2006; 27:654 8. 9. Denton M, Wilcox MH, Parnell P, et al. Role of environmental cleaning in controlling an outbreak of Acinetobacter baumannii on a neurosurgical intensive care unit. Intensive Crit Care Nurs 2005; 21:94 8. 10. de JG, Duse A, Richards G, Marais E. Back to basics optimizing the use of available resources during an outbreak of multi-drug resistant Acinetobacter spp. J Hosp Infect 2004; 57:186 7. 11. Podnos YD, Cinat ME, Wilson SE, Cooke J, Gornick W, Thrupp LD. Eradication of multi-drug resistant Acinetobacter from an intensive care unit. Surg Infect (Larchmt) 2001; 2:297 301. 12. Aygun G, Demirkiran O, Utku T, et al. Environmental contamination during a carbapenem-resistant Acinetobacter baumannii outbreak in an intensive care unit. J Hosp Infect 2002; 52:259 62. 13. Zanetti G, Blanc DS, Federli I, et al. Importation of Acinetobacter baumannii into a burn unit: a recurrent outbreak of infection associated with widespread environmental contamination. Infect Control Hosp Epidemiol 2007; 28:723 5. 14. Marchaim D, Navon-Venezia S, Leavitt A, Chmelnitsky I, Schwaber MJ, Carmeli Y. Molecular and epidemiologic study of polyclonal outbreaks of multidrug-resistant Acinetobacter baumannii infection in an Israeli hospital. Infect Control Hosp Epidemiol 2007; 28:945 50. 15. Oteo J, Garcia-Estebanez C, Miguelanez S, et al. Genotypic diversity of imipenem resistant isolates of Acinetobacter baumannii in Spain. J Infect 2007; 55:260 6. 16. Zarrilli R, Casillo R, Di PA, et al. Molecular epidemiology of a clonal outbreak of multidrug-resistant Acinetobacter baumannii in a university hospital in Italy. Clin Microbiol Infect 2007; 13:481 9. 17. Kraniotaki E, Manganelli R, Platsouka E, Grossato A, Paniara O, Palu G. Molecular investigation of an outbreak of multidrug-resistant Acinetobacter baumannii, with characterisation of class 1 integrons. Int J Antimicrob Agents 2006; 28:193 9. 18. Coelho J, Woodford N, fzal-shah M, Livermore D. Occurrence of OXA-58-like carbapenemases in Acinetobacter spp. collected over 10 years in three continents. Antimicrob Agents Chemother 2006; 50: 756 8. 19. Corbella X, Montero A, Pujol M, et al. Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J Clin Microbiol 2000; 38:4086 95. 20. Ling ML, Ang A, Wee M, Wang GC. A nosocomial outbreak of multiresistant Acinetobacter baumannii originating from an intensive care unit. Infect Control Hosp Epidemiol 2001; 22:48 9. 21. Wang SH, Sheng WH, Chang YY, et al. Healthcare-associatedoutbreak due to pan-drug resistant Acinetobacter baumannii in a surgical intensive care unit. J Hosp Infect 2003; 53:97 102. 22. Simor AE, Lee M, Vearncombe M, et al. An outbreak due to multiresistant Acinetobacter baumannii in a burn unit: risk factors for acquisition and management. Infect Control Hosp Epidemiol 2002; 23:261 7. 23. Urban C, Segal-Maurer S, Rahal JJ. Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumannii. Clin Infect Dis 2003; 36:1268 74. 24. Siegel JD, Rhinehart E, Jackson M, Chiarello L; Healthcare Infection Control Practices Advisory Committee. Management of multidrugresistant organisms in healthcare settings. Atlanta: Centers for Disease Control and Prevention, 2006. Available at: http://www.cdc.gov/nci dod/dhqp/pdf/ar/mdroguideline2006.pdf. Accessed 9 March 2007. 25. e SO, Kim NJ, Choi SH, et al. Risk factors for acquisition of imipenemresistant Acinetobacter baumannii: a case-control study. Antimicrob Agents Chemother 2004; 48:224 8. 26. Kim YA, Choi JY, Kim CK, et al. Risk factors and outcomes of bloodstream infections with metallo beta lactamase-producing Acinetobacter. Scand J Infect Dis 2007:1 7. 27. Abbo A, Navon-Venezia S, Hammer-Muntz O, Krichali T, Siegman- Igra Y, Carmeli Y. Multidrug-resistant Acinetobacter baumannii. Emerg Infect Dis 2005; 11:22 9. 28. Bonomo RA. Multiple antibiotic-resistant bacteria in long-term-care facilities: an emerging problem in the practice of infectious diseases. Clin Infect Dis 2000; 31:1414 22. 29. Mody L, Bradley SF, Strausbaugh LJ, Muder RR. Prevalence of ceftriaxone- and ceftazidime-resistant gram-negative bacteria in longterm-care facilities. Infect Control Hosp Epidemiol 2001; 22:193 4. 30. Cornaglia G, Akova M, Amicosante G, et al. Metallo-beta-lactamases as emerging resistance determinants in gram-negative pathogens: open issues. Int J Antimicrob Agents 2007; 29:380 8. 31. Nemec A, Dijkshoorn L, van der Reijden TJ. Long-term predominance of two pan-european clones among multi-resistant Acinetobacter baumannii strains in the Czech Republic. J Med Microbiol 2004; 53: 147 53. 32. Manikal VM, Landman D, Saurina G, Oydna E, Lal H, Quale J. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis 2000; 31:101 6. 33. Barbolla RE, Centron D, Di MA, et al. Identification of an epidemic carbapenem-resistant Acinetobacter baumannii strain at hospitals in Buenos Aires City. Diagn Microbiol Infect Dis 2003; 45:261 4. 34. Coelho JM, Turton JF, Kaufmann ME, et al. Occurrence of carbapenem-resistant Acinetobacter baumannii clones at multiple hospitals in London and Southeast England. J Clin Microbiol 2006; 44:3623 7. 35. Da Silva GJ, Quinteira S, Bertolo E, et al. Long-term dissemination of an OXA-40 carbapenemase-producing Acinetobacter baumannii clone in the Iberian Peninsula. J Antimicrob Chemother 2004; 54: 255 8. 36. Gales AC, Pfaller MA, Sader HS, Hollis RJ, Jones RN. Genotypic characterization of carbapenem-nonsusceptible Acinetobacter spp. isolated in Latin America. Microb Drug Resist 2004; 10:286 91. 37. Davis KA, Moran KA, McAllister CK, Gray PJ. Multidrug-resistant Acinetobacter extremity infections in soldiers. Emerg Infect Dis 2005; 11:1218 24. 38. Centers for Disease Control and Prevention. Acinetobacter baumannii infections among patients at military medical facilities treating injured U.S. service members, 2002 2004. MMWR Morb Mortal Wkly Rep 2004; 53:1063 6. 39. Hujer KM, Hujer AM, Hulten EA, et al. Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. Antimicrob Agents Chemother 2006; 50:4114 23. 40. Hawley JS, Murray CK, Griffith ME, et al. Susceptibility of acinetobacter strains isolated from deployed U.S. military personnel. Antimicrob Agents Chemother 2007; 51:376 8. 41. Murray CK, Roop SA, Hospenthal DR, et al. Bacteriology of war wounds at the time of injury. Mil Med 2006; 171:826 9. 42. Yun HC, Murray CK, Roop SA, Hospenthal DR, Gourdine E, Dooley DP. Bacteria recovered from patients admitted to a deployed U.S. military hospital in Baghdad, Iraq. Mil Med 2006; 171:821 5. 1260 CID 2008:46 (15 April) ANTIMICROBIAL RESISTANCE

43. Scott P, Deye G, Srinivasan A, et al. An outbreak of multidrug-resistant Acinetobacter baumannii-calcoaceticus complex infection in the US military health care system associated with military operations in Iraq. Clin Infect Dis 2007; 44:1577 84. 44. Griffith ME, Lazarus DR, Mann PB, Boger JA, Hospenthal DR, Murray CK. Acinetobacter skin carriage among US army soldiers deployed in Iraq. Infect Control Hosp Epidemiol 2007; 28:720 2. 45. Griffith ME, Ceremuga JM, Ellis MW, Guymon CH, Hospenthal DR, Murray CK. Acinetobacter skin colonization of US Army Soldiers. Infect Control Hosp Epidemiol 2006; 27:659 61. 46. Tien HC, Battad A, Bryce EA, et al. Multi-drug resistant Acinetobacter infections in critically injured Canadian Forces soldiers. BMC Infect Dis 2007; 7:95. 47. Jones A, Morgan D, Walsh A, et al. Importation of multidrug-resistant Acinetobacter spp infections with casualties from Iraq. Lancet Infect Dis 2006; 6:317 8. 48. Turton JF, Kaufmann ME, Gill MJ, et al. Comparison of Acinetobacter baumannii isolates from the United Kingdom and the United States that were associated with repatriated casualties of the Iraq conflict. J Clin Microbiol 2006; 44:2630 4. 49. Sunenshine RH, Wright MO, Maragakis LL, et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 2007; 13:97 103. 50. Seifert H, Strate A, Pulverer G. Nosocomial bacteremia due to Acinetobacter baumannii: clinical features, epidemiology, and predictors of mortality. Medicine (Baltimore) 1995; 74:340 9. 51. Kwon KT, Oh WS, Song JH, et al. Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. J Antimicrob Chemother 2007; 59:525 30. 52. Falagas ME, Kopterides P, Siempos II. Attributable mortality of Acinetobacter baumannii infection among critically ill patients. Clin Infect Dis 2006; 43:389 90. 53. Lee NY, Lee HC, Ko NY, et al. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol 2007; 28:713 9. 54. Abbo A, Carmeli Y, Navon-Venezia S, Siegman-Igra Y, Schwaber MJ. Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes. Eur J Clin Microbiol Infect Dis 2007; 26:793 800. 55. Albrecht MA, Griffith ME, Murray CK, et al. Impact of Acinetobacter infection on the mortality of burn patients. J Am Coll Surg 2006; 203:546 50. 56. Blot S, Vandewoude K, Colardyn F. Nosocomial bacteremia involving Acinetobacter baumannii in critically ill patients: a matched cohort study. Intensive Care Med 2003; 29:471 5. 57. Chen HP, Chen TL, Lai CH, et al. Predictors of mortality in Acinetobacter baumannii bacteremia. J Microbiol Immunol Infect 2005; 38: 127 36. 58. Choi JY, Park YS, Kim CO, et al. Mortality risk factors of Acinetobacter baumannii bacteraemia. Intern Med J 2005; 35:599 603. 59. Falagas ME, Kasiakou SK, Rafailidis PI, Zouglakis G, Morfou P. Comparison of mortality of patients with Acinetobacter baumannii bacteraemia receiving appropriate and inappropriate empirical therapy. J Antimicrob Chemother 2006; 57:1251 4. 60. The cost of antibiotic resistance: effect of resistance among Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa on length of hospital stay. Infect Control Hosp Epidemiol 2002; 23:106 8. 61. Garnacho J, Sole-Violan J, Sa-Borges M, Diaz E, Rello J. Clinical impact of pneumonia caused by Acinetobacter baumannii in intubated patients: a matched cohort study. Crit Care Med 2003; 31:2478 82. 62. Lockhart SR, Abramson MA, Beekmann SE, et al. Antimicrobial resistance among gram negative bacilli as causes of infections in intensive care unit patients in the United States between 1993 and 2004. J Clin Microbiol 2007; 45:3352 9. 63. Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 2006; 43(Suppl 2):49 56. 64. Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol 2006; 55:1619 29. 65. Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001 2004). Clin Microbiol Infect 2006; 12:315 21. 66. Urban C, Mariano N, Rahal JJ, et al. Polymyxin B-resistant Acinetobacter baumannii clinical isolate susceptible to recombinant BPI and cecropin P1. Antimicrob Agents Chemother 2001; 45:994 5. 67. Thomson JM, Bonomo RA. The threat of antibiotic resistance in gram-negative pathogenic bacteria: beta-lactams in peril! Curr Opin Microbiol 2005; 8:518 24. 68. Rice LB. Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 2006; 43(Suppl 2):100-5. 69. fzal-shah M, Woodford N, Livermore DM. Characterization of OXA- 25, OXA-26, and OXA-27, molecular class D beta-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 2001; 45:583 8. 70. Brown S, Amyes S. OXA b-lactamases in Acinetobacter: the story so far. J Antimicrob Chemother 2006; 57:1 3. 71. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-beta-lactamases: the quiet before the storm? Clin Microbiol Rev 2005; 18: 306 25. 72. Lee K, Lee WG, Uh Y, Ha GY, Cho J, Chong Y. VIM- and IMP-type metallo-beta-lactamase-producing Pseudomonas spp. and Acinetobacter spp. in Korean hospitals. Emerg Infect Dis 2003; 9:868 71. 73. Bou G, Oliver A, Martinez-Beltran J. OXA-24, a novel class D betalactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain. Antimicrob Agents Chemother 2000; 44:1556 61. 74. Mussi MA, Limansky AS, Viale AM. Acquisition of resistance to carbapenems in multidrug-resistant clinical strains of Acinetobacter baumannii: natural insertional inactivation of a gene encoding a member of a novel family of beta-barrel outer membrane proteins. Antimicrob Agents Chemother 2005; 49:1432 40. 75. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant gram-negative bacteria. Int J Antimicrob Agents 2005; 25:11 25. 76. Fournier PE, Vallenet D, Barbe V, et al. Comparative genomics of multidrug resistance in Acinetobacter baumannii. PLoS Genet 2006; 2:7. 77. Harris AD, McGregor JC, Furuno JP. What infection control interventions should be undertaken to control multidrug-resistant gramnegative bacteria? Clin Infect Dis 2006; 43(Suppl 2):57-61. 78. Jones RN, Sader HS, Fritsche TR, Rhomberg PR. Carbapenem susceptibility discords among Acinetobacter isolates. Clin Infect Dis 2006; 42:158. 79. Jones RN, Deshpande L, Fritsche TR, Sader HS. Determination of epidemic clonality among multidrug-resistant strains of Acinetobacter spp. and Pseudomonas aeruginosa in the MYSTIC Programme (USA, 1999 2003). Diagn Microbiol Infect Dis 2004; 49:211 6. 80. Ikonomidis A, Pournaras S, Maniatis AN, Legakis NJ, Tsakris A. Discordance of meropenem versus imipenem activity against Acinetobacter baumannii. Int J Antimicrob Agents 2006; 28:376 7. 81. Brauers J, Frank U, Kresken M, Rodloff AC, Seifert H. Activities of various beta-lactams and beta-lactam/beta-lactamase inhibitor combinations against Acinetobacter baumannii and Acinetobacter DNA group 3 strains. Clin Microbiol Infect 2005; 11:24 30. 82. Higgins PG, Wisplinghoff H, Stefanik D, Seifert H. In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epide- ANTIMICROBIAL RESISTANCE CID 2008:46 (15 April) 1261

miologically characterized multidrug-resistant Acinetobacter baumannii strains. Antimicrob Agents Chemother 2004; 48:1586 92. 83. Wood GC, Hanes SD, Croce MA, Fabian TC, Boucher BA. Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia. Clin Infect Dis 2002; 34:1425 30. 84. Levin AS, Levy CE, Manrique AE, Medeiros EA, Costa SF. Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam. Int J Antimicrob Agents 2003; 21:58 62. 85. Seifert H, Stefanik D, Wisplinghoff H. Comparative in vitro activities of tigecycline and 11 other antimicrobial agents against 215 epidemiologically defined multidrug-resistant Acinetobacter baumannii isolates. J Antimicrob Chemother 2006; 58:1099 100. 86. Pachon-Ibanez ME, Jimenez-Mejias ME, Pichardo C, Llanos AC, Pachon J. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother 2004; 48:4479 81. 87. Insa R, Cercenado E, Goyanes MJ, Morente A, Bouza E. In vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii and Stenotrophomonas maltophilia. J Antimicrob Chemother 2007; 59:583 5. 88. Jones RN, Ferraro MJ, Reller LB, Schreckenberger PC, Swenson JM, Sader HS. Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp. J Clin Microbiol 2007; 45:227 30. 89. Peleg AY, Potoski BA, Rea R, et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 2007; 59:128 31. 90. Reid GE, Grim SA, Aldeza CA, Janda WM, Clark NM. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy 2007; 27:1198 201. 91. Navon-Venezia S, Leavitt A, Carmeli Y. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 2007; 59:772 4. 92. Peleg AY, Adams J, Paterson DL. Tigecycline efflux as a mechanism for nonsusceptibility in Acinetobacter baumannii. Antimicrob Agents Chemother 2007; 51:2065 9. 93. Ruzin A, Keeney D, Bradford PA. AdeABC multidrug efflux pump is associated with decreased susceptibility to tigecycline in Acinetobacter calcoaceticus-acinetobacter baumannii complex. J Antimicrob Chemother 2007; 59:1001 4. 94. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005; 40:1333 41. 95. Li J, Nation RL, Turnidge JD, et al. Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. Lancet Infect Dis 2006; 6:589 601. 96. Levin AS, Barone AA, Penco J, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28: 1008 11. 97. Garnacho-Montero J, Ortiz-Leyba C, Fernandez-Hinojosa E, et al. Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive Care Med 2005; 31:649 55. 98. Holloway KP, Rouphael NG, Wells JB, King MD, Blumberg HM. Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit. Ann Pharmacother 2006; 40:1939 45. 99. Kallel H, Bahloul M, Hergafi L, et al. Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU. Int J Antimicrob Agents 2006; 28:366 9. 100. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003; 36:1111 8. 101. Linden PK, Paterson DL. Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia. Clin Infect Dis 2006; 43(Suppl 2):89-94. 102. Kasiakou SK, Michalopoulos A, Soteriades ES, Samonis G, Sermaides GJ, Falagas ME. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother 2005; 49:3136 46. 103. Markou N, Apostolakos H, Koumoudiou C, et al. Intravenous colistin in the treatment of sepsis from multiresistant gram-negative bacilli in critically ill patients. Crit Care 2003; 7:78-83. 104. Katragkou A, Roilides E. Successful treatment of multidrug-resistant Acinetobacter baumannii central nervous system infections with colistin. J Clin Microbiol 2005; 43:4916 7. 105. Fulnecky EJ, Wright D, Scheld WM, Kanawati L, Shoham S. Amikacin and colistin for treatment of Acinetobacter baumannii meningitis. J Infect 2005; 51:249-51. 106. Benifla M, Zucker G, Cohen A, Alkan M. Successful treatment of Acinetobacter meningitis with intrathecal polymyxin E. J Antimicrob Chemother 2004; 54:290 2. 107. Al SN, Memish ZA, Cherfan A, Al SA. Post-neurosurgical meningitis due to multidrug-resistant Acinetobacter baumanii treated with intrathecal colistin: case report and review of the literature. J Chemother 2006; 18:554 8. 108. Ng J, Gosbell IB, Kelly JA, Boyle MJ, Ferguson JK. Cure of multiresistant Acinetobacter baumannii central nervous system infections with intraventricular or intrathecal colistin: case series and literature review. J Antimicrob Chemother 2006; 58:1078 81. 109. Falagas ME, Bliziotis IA, Tam VH. Intraventricular or intrathecal use of polymyxins in patients with gram-negative meningitis: a systematic review of the available evidence. Int J Antimicrob Agents 2007; 29: 9 25. 110. Giamarellos-Bourboulis EJ, Xirouchaki E, Giamarellou H. Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 2001; 40:117 20. 111. Petrosillo N, Chinello P, Proietti MF, et al. Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events. Clin Microbiol Infect 2005; 11:682 3. 112. Pantopoulou A, Giamarellos-Bourboulis EJ, Raftogannis M, et al. Colistin offers prolonged survival in experimental infection by multidrug-resistant Acinetobacter baumannii: the significance of co-administration of rifampicin. Int J Antimicrob Agents 2007; 29:51 5. 113. Montero A, Ariza J, Corbella X, et al. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J Antimicrob Chemother 2004; 54:1085 91. 114. Saballs M, Pujol M, Tubau F, et al. Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 2006; 58:697 700. 115. Rodriguez-Hernandez MJ, Pachon J, Pichardo C, et al. Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia. J Antimicrob Chemother 2000; 45:493 501. 116. Bernabeu-Wittel M, Pichardo C, Garcia-Curiel A, et al. Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia. Clin Microbiol Infect 2005; 11:319 25. 117. Haddad FA, Van HK, Carbonaro C, Guero-Rosenfeld M, Wormser GP. Evaluation of antibiotic combinations against multidrug-resistant Acinetobacter baumannii using the E-test. Eur J Clin Microbiol Infect Dis 2005; 24:577 9. 118. Ko WC, Lee HC, Chiang SR, et al. In vitro and in vivo activity of 1262 CID 2008:46 (15 April) ANTIMICROBIAL RESISTANCE